why choose us

First received: September 15, 2023

Clinical Trial: Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed and Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Brief Summary: Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases.While still considered an incurable disease, new treatments have improved outcomes dramatically over the last two decades.Around the turn of the millennium, classical cytotoxic chemotherapy and radiation were the only available treatment modalities and median OS was estimated at 2-3 years.Currently, there are now 17 FDA-approved anti-myeloma agents and median OS is approaching 10…

Read more